ACQUISITION AGREEMENT by and among INVERNESS MEDICAL INNOVATIONS, INC., ACON LABORATORIES, INC., AZURE INSTITUTE, INC., LBI, INC., OAKVILLE HONG KONG CO., LTD., ACON BIOTECH (HANGZHOU) CO., LTD., AND KARSSON OVERSEAS LTD. February 24, 2006Acquisition Agreement • February 24th, 2006 • Inverness Medical Innovations Inc • In vitro & in vivo diagnostic substances • Delaware
THIS ACQUISITION AGREEMENT (this “Agreement”) is entered into as of February 24, 2006 by and among: (i) Inverness Medical Innovations, Inc., a Delaware corporation (“Buyer”); (ii) ACON Laboratories, Inc., a California corporation (“ACON Labs”), AZURE Institute, Inc., a California corporation (“Azure”), LBI Inc., a British Virgin Islands company (“LBI”), Oakville Hong Kong Co., Ltd., a Hong Kong company (“Oakville”), and Acon Biotech (Hangzhou) Co., Ltd., a wholly foreign owned enterprise (“WFOE”) established in the People’s Republic of China (“PRC” or “China”) (“Acon Bio” and together with Acon Labs, Azure, LBI, Oakville and ACON Bio, “ACON” or the “Seller Entities”); and (iii) Karsson Overseas Ltd., a British Virgin Islands company (“Parent”) and direct or indirect parent of the Seller Entities and other Affiliates (as defined herein) of the Seller Entities that are parties to agreements entered into connection with the transactions contemplated hereby.
